Literature DB >> 17142109

Time trends of gastroesophageal reflux disease: a systematic review.

Hashem B El-Serag1.   

Abstract

There is a perception that the prevalence of gastroesophageal reflux disease (GERD) is increasing, but few studies have directly tackled this issue. By using a systematic approach, this review aimed to assess objectively whether the prevalence of GERD is changing with time. First, population-based studies that reported the prevalence of at least weekly heartburn and/or acid regurgitation were subjected to a time-trend analysis with a Poisson regression model. Second, population-based studies reporting the prevalence of GERD symptoms at 2 time points in the same source population were reviewed. Third, longitudinal studies that charted the prevalence of GERD symptoms and esophagitis in primary and secondary care were examined. The Poisson model revealed a significant (P < .0001) trend for an increase in the prevalence of reflux symptoms in the general population over time. Separately, significant increases with time were found for North America (P = .0005) and Europe (P < .0001) but not Asia (P = .49). Studies of the same source population over time indicated an increase in the prevalence of GERD in the U.S., Singapore, and China but not Sweden. An increase in the prevalence of GERD or esophagitis was found in the majority of longitudinal studies. There is evidence that the prevalence of GERD has increased during the past 2 decades. If this trend continues, it could contribute to the rapidly increasing incidence of more serious complications associated with GERD, such as esophageal adenocarcinoma, as well as costs to healthcare systems and employers.

Entities:  

Mesh:

Year:  2006        PMID: 17142109     DOI: 10.1016/j.cgh.2006.09.016

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  125 in total

1.  The value of branded proton pump inhibitors: formulary considerations.

Authors:  David A Peura; Rosemary R Berardi; Javier Gonzalez; Louis Brunetti
Journal:  P T       Date:  2011-07

2.  The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model.

Authors:  Chung Yin Kong; Kevin J Nattinger; Tristan J Hayeck; Zehra B Omer; Y Claire Wang; Stuart J Spechler; Pamela M McMahon; G Scott Gazelle; Chin Hur
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-19       Impact factor: 4.254

Review 3.  Laparoscopic Nissen fundoplication with or without short gastric vessel division: a meta-analysis.

Authors:  Kamran Khatri; Muhammad S Sajid; Robert Brodrick; Mirza K Baig; Mazin Sayegh; Krishna K Singh
Journal:  Surg Endosc       Date:  2011-11-01       Impact factor: 4.584

Review 4.  Gastroesophageal reflux disease--from reflux episodes to mucosal inflammation.

Authors:  Arne Kandulski; Peter Malfertheiner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-22       Impact factor: 46.802

5.  Gastroesophageal reflux disease: Important considerations for the older patients.

Authors:  Maxwell M Chait
Journal:  World J Gastrointest Endosc       Date:  2010-12-16

6.  Population based study to assess prevalence and risk factors of gastroesophageal reflux disease in a high altitude area.

Authors:  Sushil Kumar; Saurabh Sharma; Tsering Norboo; Diskit Dolma; Angchuk Norboo; Tsering Stobdan; S Rohatgi; K Munot; Vineet Ahuja; Anoop Saraya
Journal:  Indian J Gastroenterol       Date:  2010-12-23

7.  GERD symptoms in the general population: prevalence and severity versus care-seeking patients.

Authors:  Erica Cohen; Roger Bolus; Dinesh Khanna; Ron D Hays; Lin Chang; Gil Y Melmed; Puja Khanna; Brennan Spiegel
Journal:  Dig Dis Sci       Date:  2014-05-09       Impact factor: 3.199

8.  Tumor-infiltrating neutrophils predict poor outcome in adenocarcinoma of the esophagogastric junction.

Authors:  Pingping Hu; Zhaofei Pang; Hongchang Shen; Guanghui Wang; Haifeng Sun; Jiajun Du
Journal:  Tumour Biol       Date:  2014-12-07

9.  Endoluminal fundoplication (ELF) for GERD using EsophyX: a 12-month follow-up in a single-center experience.

Authors:  Alessandro Repici; Uberto Fumagalli; Alberto Malesci; Roberta Barbera; Camilla Gambaro; Riccardo Rosati
Journal:  J Gastrointest Surg       Date:  2009-11-10       Impact factor: 3.452

Review 10.  Economic evaluations of gastroesophageal reflux disease medical management.

Authors:  Andrew J Gawron; Dustin D French; John E Pandolfino; Colin W Howden
Journal:  Pharmacoeconomics       Date:  2014-08       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.